Form 4: Harrow CCO Granted 40,000 Performance-Based RSUs

Harrow, Inc.'s Chief Commercial Officer, Patrick Sullivan, was granted 40,000 Restricted Stock Units with both performance and time-based vesting conditions.

Summary

• Patrick William Sullivan, Chief Commercial Officer of Harrow, Inc. (HROW), was granted 40,000 Restricted Stock Units (RSUs).
• The grant date for these RSUs was January 30, 2026.
• 25,000 RSUs are performance-based, vesting when Harrow's revenue reaches $230,000,000 in a calendar quarterly period, with a five-year term.
• 15,000 RSUs are time-based, vesting in full after three years from the award date, specifically on January 30, 2029.
• Each RSU represents the right to receive one share of Harrow's common stock upon vesting.
• The RSUs were granted under the Issuer's 2025 Incentive and Awards Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns executive compensation with specific performance targets and long-term retention, which is generally favorable for corporate governance and shareholder value.

Positives

• The grant of performance-based RSUs aligns the Chief Commercial Officer's incentives directly with the company's revenue growth targets, benefiting shareholders.
• The time-based RSUs provide retention incentives for key management personnel.
• The awards are made under an existing incentive plan, indicating structured compensation practices.

Risks

• Achievement of the $230,000,000 quarterly revenue target for the performance-based RSUs is not guaranteed and depends on future business performance.
• The value of the RSUs upon vesting is subject to the future market price of Harrow's common stock.

Future Outlook

The performance-based RSU grant implies a strategic focus on achieving significant revenue growth, targeting $230,000,000 in a calendar quarterly period, which suggests management's confidence in future expansion.

Industry Context

StockSavvy.ai notes that performance-based and time-based RSU grants are standard practice in executive compensation across the pharmaceutical and biotech industries. This structure aims to balance long-term retention with incentivizing specific financial achievements, a common approach to align executive interests with shareholder value creation.

Comparison to Industry Standards

• The use of both performance-based and time-based vesting for executive compensation is a common practice, similar to structures seen at companies like Bausch Health Companies Inc. or Alcon Inc., which often tie executive incentives to revenue growth or share price performance over multi-year periods.
• The specific revenue target of $230 million for vesting 25,000 RSUs provides a clear, measurable goal, comparable to operational milestones set by peers in the specialty pharmaceutical sector for their executive incentive plans.
• A three-year vesting period for time-based RSUs is typical for executive retention, aligning with industry benchmarks for long-term incentive plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with company performance and revenue growth.
• Management: The Chief Commercial Officer receives a significant incentive package tied to company performance and retention.

Next Steps

• Harrow, Inc. will need to achieve $230,000,000 in revenue in a calendar quarterly period for the performance-based RSUs to vest.
• The time-based RSUs will vest on January 30, 2029.

Key Dates

Keywords

Harrow Inc, HROW, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Patrick Sullivan, Chief Commercial Officer, Performance-Based Vesting, Time-Based Vesting, SEC Form 4